Drug intelligence / Profile preview

ATR siRNA

Development stage
Preclinical
Lead developer
University of Glasgow
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01

Overview

ATR siRNA refers to small interfering RNA molecules designed to silence the expression of the Ataxia telangiectasia and rad3-related (ATR) kinase. ATR is a critical DNA damage response (DDR) kinase that coordinates the cellular response to DNA replication stress and damage. In oncological research, particularly in glioblastoma (GBM), ATR siRNA is utilized to investigate the role of ATR in tumor cell invasion, motility, and macropinocytic vesicle trafficking. By knocking down ATR expression, researchers have demonstrated defects in cell velocity and integrin internalisation, suggesting that ATR facilitates malignant cell invasion beyond its traditional role in DNA repair. While small molecule ATR inhibitors are in clinical development, ATR siRNA is primarily employed as a research tool to validate the therapeutic potential of targeting the ATR pathway.

Other names
ATR-targeting siRNAsiRNA-ATR
02

Targets

ATR (ATR serine/threonine kinase)

Beyond the preview

Go deeper on ATR siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATR siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call